Vireo GrowthVREOF +2.36%47 PB Ratio is 1.22 as of Jul. 08, 2026, which is 75% below its 10-year median of 4.80. GuruFocus rates VREOF with a GF Score™ of 47/100 and a GF Value™ of $9.69 (Fairly Valued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Vireo Growth ranks better than 66.81% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-08), Vireo Growth's share price is $9.98. Vireo Growth's Book Value per Share for the quarter that ended in Mar. 2026 was $8.17. Hence, Vireo Growth's PB Ratio of today is 1.22.
Good Sign:
Vireo Growth Inc stock PB Ratio (=1.25) is close to 10-year low of 1.25.
The historical rank and industry rank for Vireo Growth's PB Ratio or its related term are showing as below:
VREOF'
s PB Ratio Range Over the Past 10 Years
Min: 1.22 Med: 4.8 Max: 23.58
Current: 1.25
During the past 13 years, Vireo Growth's highest PB Ratio was 23.58. The lowest was 1.22. And the median was 4.80.
VREOF's PB Ratio is ranked better than 66.81% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs VREOF: 1.25
During the past 12 months, Vireo Growth's average Book Value Per Share Growth Rate was 89.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 198.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vireo Growth was 198.90% per year. The lowest was -60.20% per year. And the median was 7.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vireo Growth PB Ratio Related Terms
Vireo Growth PB Ratio Historical Data
* Premium members only.
The historical data trend for Vireo Growth's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vireo Growth's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vireo Growth's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vireo Growth (VREOF) has a PB Ratio of 1.22 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vireo Growth and its competitors. This is 75% below median its historical median of 4.80. Over the past decade, Vireo Growth's PB Ratio has ranged from 1.22 to 23.58. According to the industry distribution chart, Vireo Growth ranks #305 out of 919 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Vireo Growth's PB Ratio too high?
Vireo Growth's current PB Ratio of 1.22 is 75% below median its 10-year median of 4.80. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 23.58. The Drug Manufacturers industry median PB Ratio is 1.91. Vireo Growth's value of 1.22 is 36.1% below this industry median. Based on the distribution chart, Vireo Growth ranks #305 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vireo Growth has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #305 out of 919 companies for PB Ratio. This puts Vireo Growth in the upper half of its industry. The industry median PB Ratio is 1.91. Vireo Growth's value of 1.22 is 36.1% below this benchmark. Historically, Vireo Growth's own PB Ratio has ranged from 1.22 to 23.58 over the past decade. While the company's 10-year median is 4.80 vs. the industry median of 1.91, Vireo Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current PB Ratio of 1.22 is 36.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current PB Ratio is 1.22, which is 75% below median its own 10-year median of 4.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $9.69, compared to a current price of $9.98 — trading 3% above its estimated fair value. The current PB Ratio is 1.22, which is 75% below median its 10-year median of 4.80 and 36.1% below the Drug Manufacturers industry median of 1.91. Vireo Growth's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vireo Growth (VREOF), the current PB Ratio is 1.22 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $9.98 is trading 3% above its estimated GF Value™ of $9.69.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
PB Ratio: 1.22 (75% below median its 10-year median of 4.80)
GF Value™: $9.69 vs. price of $9.98 (3% above fair value)
Industry Position: 36.1% below the Drug Manufacturers median (#305 of 919)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
47GF Score
Get the complete analysis for VREOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
